Ocera Therapeutics, Inc. (Nasdaq:OCRX), a biopharmaceutical company focused on innovative therapeutics for orphan liver disease, announced its financial results and other information for the fourth quarter and year ended December 31, 2013. Revenues from continuing operations for the fourth quarter were $0.1 million compared to no revenue for the same period in 2012. Net loss for the fourth quarter from continuing operations was $6.6 million and $0.7 million from discontinued operations, compared to a net loss of $0.7 million in the same period of 2012. As of December 31, 2013, Ocera had cash, cash equivalents and investments of $47.2 million. Ocera Therapeutics Inc (NASDAQ:OCRX) stock opened at $14.46 in last session, and closed at $15.05, while the day range of OCRX stock is $14.24-$15.58. The stock showed a positive weekly performance of -8.51%.
Celladon Corporation (NASDAQ:CLDN)’s shares climbed 5.87% to $12.27. The company on Mar. 4 announced it has completed enrollment and randomized 250 patients in the phase 2b trial titled “Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease,” known as CUPID 2, which is evaluating the efficacy and safety of MYDICAR (AAV1/SERCA2a) in patients with NYHA class III/IV symptoms of systolic heart failure. Celladon Corp (NASDAQ:CLDN) stock opened at $13.90, in last session and closed at $14.66, by gained 8.27%.The 52 week range was $7.45-$15.48.Company’s market capitalization is $271.21 million.
Piper Jaffray set a $45.00 price target on shares of Insmed Incorporated (NASDAQ:INSM) stock in a research note issued on Tuesday, Analyst Ratings Network.com reports. Piper Jaffray’s target price indicates a potential upside of 170.92% from the stock’s previous close. Insmed Incorporated (NASDAQ:INSM) stock gained 5.94% and finished the last session at $18.91. The EPS of the stock remained -1.59.Company’s market capitalization is $742.48 million.
A number of analysts have recently weighed in on Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares. Analysts at Piper Jaffray initiated coverage on shares of Vanda Pharmaceuticals in a research note on Tuesday, November 26th. They set an “overweight” rating and a $21.00 price target on the stock. On a related note, analysts at Jefferies Group raised their price target on shares of Vanda Pharmaceuticals from $13.00 to $20.00 in a research note on Friday, November 15th. They now have a “buy” rating on the stock. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) stock opened the session at $16.50, and closed the session at $17.53. The 52 week range of the VNDA stock remained $3.57-$18.00 and the day range was $16.43-$18.00.